Shanghai Junshi Biosciences (HKG:1877, SHA:688180) will conduct clinical trials on JS212 injection after receiving approval from China's National Medical Products Administration, according to a Hong Kong Stock Exchange disclosure on Thursday.
The drug will be tested as a treatment for advanced malignant solid tumors in conditions such as lung cancer, breast cancer, and head and neck cancer, the pharmaceutical company said.
Junshi Bio's Hong Kong shares dropped over 4% and Shanghai shares fell less than 2% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。